If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Block Listing Six Monthly Return

2 Jan 2019 07:00

RNS Number : 7694L
Ergomed plc
02 January 2019
 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 2 January 2019

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

2 July 2018

To:

31 December 2018

Balance of unallotted securities under scheme(s) from previous return:

1,800,000 (original admission)

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

55,000

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,745,000

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

Total number of securities in issue at the end of the period

45,016,438 ordinary shares of 1p each

 

Name of contact:

Nick Blech - Deputy CFO

Telephone number of contact:

+44 (0)7768 547372

 

 Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)

Stuart Jackson (Chief Financial Officer)

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Broker)

 

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

 

ergomed@consilium-comms.com

MC-Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRFEWFWAFASEEE
Date   Source Headline
2nd Jun 20234:48 pmRNSTR1 Notification
26th May 20238:38 amRNSNotice of AGM and Annual Report
19th Apr 20237:00 amRNSDirector's Dealing
17th Apr 20237:00 amRNSHolding(s) in Company
13th Apr 20233:27 pmRNSHoldings in Company
3rd Apr 20239:51 amRNSHolding(s) in Company
3rd Apr 20237:00 amRNSTotal Voting Rights
30th Mar 20233:37 pmRNSHolding(s) in Company
21st Mar 20237:00 amRNSErgomed Preliminary Results 2022
17th Mar 202311:39 amRNSHoldings in Company
1st Mar 20237:07 amRNSTotal Voting Rights
16th Feb 20231:44 pmRNSHolding(s) in Company
14th Feb 20237:01 amRNSNotice of Preliminary Results
1st Feb 20237:00 amRNSTotal Voting Rights
25th Jan 20237:00 amRNSJonathan Curtain appointed CFO
25th Jan 20237:00 amRNSErgomed 2022 Trading Update
20th Jan 20235:23 pmRNSHolding(s) in Company
20th Jan 20239:38 amRNSHolding(s) in Company
3rd Jan 20237:00 amRNSTotal Voting Rights and Block Listing Return
5th Dec 20227:00 amRNSDirector Dealings
2nd Dec 20227:00 amRNSJohn Dawson appointed Senior Independent Director
1st Dec 20227:00 amRNSTotal Voting Rights
22nd Nov 20227:00 amRNSExercise of Share Options and Total Voting Rights
21st Nov 202210:46 amEQSErgomed (ERGO): Two key management changes
17th Nov 20227:00 amRNSErgomed Strengthens Executive Management Team
16th Nov 20227:00 amRNSExercise of Share Options and Total Voting Rights
1st Nov 20224:16 pmRNSExercise of Share Options and Total Voting Rights
1st Nov 20227:00 amRNSTotal Voting Rights
20th Oct 20222:09 pmRNSHolding(s) in Company
14th Oct 20224:09 pmRNSHolding(s) in Company
13th Oct 20227:00 amRNSHolding(s) in Company
4th Oct 202212:52 pmEQSErgomed (ERGO): Poised for a strong FY22
3rd Oct 20227:00 amRNSTotal Voting Rights
27th Sep 20227:00 amRNSErgomed Interim results 2022
2nd Sep 20227:00 amRNSHolding(s) in Company
1st Sep 20227:00 amRNSTotal Voting Rights
25th Aug 20227:00 amRNSErgomed Notice of Results
19th Aug 20222:49 pmRNSHolding(s) in Company
1st Aug 20228:10 amEQSErgomed (ERGO): Sustained growth momentum in H122
1st Aug 20227:00 amRNSDirector Dealing
1st Aug 20227:00 amRNSTotal Voting Rights
26th Jul 20227:00 amRNSErgomed H1 2022 Trading Update
1st Jul 20227:00 amRNSTotal Voting Rights and Block Listing Return
10th Jun 202211:21 amRNSResults of 2022 Annual General Meeting
10th Jun 20227:00 amRNSErgomed Annual General Meeting Statement
10th Jun 20227:00 amRNSAnne Whitaker appointed to the Board as NED
1st Jun 20227:00 amRNSErgomed plc Total Voting Rights
13th May 20227:00 amRNSErgomed Notice of AGM and Annual Report
3rd May 20228:49 amRNSErgomed plc Total Voting Rights
28th Apr 20227:01 amEQSErgomed (ERGO): Healthy fundamentals for 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.